Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.70 |
| ▸ | GABRA1 | P14867 | 15/20 | 0.65 |
| ▸ | GABRB2 | P47870 | 15/20 | 0.65 |
| ▸ | CNR2 | P34972 | 3/20 | 0.65 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22296373 | 0.90 | ALOX5 (0.59) | ALOX5GABRA1GABRB2CNR2GABRA5 | |
| SCHEMBL6947612 | 0.84 | MEN1 (0.70) | ALOX5MEN1CYP3A4KMT2ATDP1 | |
| SCHEMBL13978616 | 0.80 | GABRA1 (1.00) | ALOX5GABRA1GABRB2CNR2GABRA5 | |
| SCHEMBL18313888 | 0.77 | ALOX5 (1.00) | ALOX5GABRA1GABRB2CNR2GABRA5 | |
| SCHEMBL34470434 | 0.77 | ALOX5 (1.00) | ALOX5GABRA1GABRB2CNR2GABRA5 | |
| Methylhonokiol SCHEMBL29997213 | 0.76 | GABRA1 (1.00) | ALOX5GABRA1GABRB2CNR2GABRA5 | |
| Methylhonokiol SCHEMBL12391677 | 0.76 | GABRA1 (1.00) | ALOX5GABRA1GABRB2CNR2GABRA5 | |
| Methylhonokiol SCHEMBL31046735 | 0.76 | GABRA1 (1.00) | ALOX5GABRA1GABRB2CNR2GABRA5 | |
| SCHEMBL34470194 | 0.75 | ALOX5 (0.78) | ALOX5GABRA1GABRB2CNR2GABRA5 | |
| SCHEMBL13978629 | 0.73 | GABRA1 (0.81) | ALOX5GABRA1GABRB2CNR2GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134737-A1 | MITO-HONOKIOL COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | THE MEDICAL COLLEGE OF WISCONSIN, INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134737-A1 | MITO-HONOKIOL COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | MFN2, MT-ND2, PCK2 | ALOX5 346/4885GABRA1 4171/4885GABRB2 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.